Officer and Director Stock Transaction Filing

Beth C. Seidenberg, a director at Kyverna Therapeutics, Inc., reported a stock transaction on May 27, 2026. Seidenberg acquired 5,093 shares of Common Stock at a price of $0.0 per share, increasing her post-transaction holdings to 21,727 shares. Additionally, Seidenberg was granted a stock option to purchase 20,582 shares of Common Stock, with an exercise price of $8.59 per share, vesting on May 27, 2027, or prior to the 2027 annual meeting. The filing also indicates indirect holdings of 3,787,940 and 869,317 shares of Common Stock through Westlake BioPartners Fund I, L.P. and Westlake BioPartners Opportunity Fund I, L.P., respectively. The reporting owner disclaims beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.